BDUK Therapeutics
Biotechnology Research • 
Hashayarot 18, Jerusalem, Israel • 1-10 Employees
Company overview
| Headquarters | Hashayarot 18, Jerusalem, 9254431, IL |
| Website | |
| NAICS | 541714 |
| Founded | 2024 |
| Employees | 1-10 |
Key Contact at BDUK Therapeutics
Yaron Suissa
Chief Operations Officer & Co-Founder
BDUK Therapeutics Email Formats
BDUK Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@bduk-tx.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@bduk-tx.com | 66.7% |
{first name}{last name} | johndoe@bduk-tx.com | 33.3% |
About BDUK Therapeutics
BDUK Therapeutics develops a groundbreaking liver cancer therapy, utilizing pre-existing drugs combined into a novel and highly potent therapeutic product for an orphan drug disease with optimal G2M strategy. The current Liver cancer market size is $11 Bn, with no effective therapy (20% 5yr survival rate). The technology was developed in the Hebrew University and received the prestigious European Research Council (ERC) grant.
BDUK Therapeutics revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
BDUK Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
BDUK Therapeutics has never raised funding before.
United States
Canada
France
Australia
United KingdomFrequently asked questions
4.8
40,000 users
